Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours

被引：4
|
作者：
Karp, D. D. [1 ]
Dronca, R. S. [2 ]
Camidge, R. [3 ]
Costello, B. A. [4 ]
Mansfield, A. S. [5 ]
Ames, T. D. [6 ]
Jimeno, J. M. [7 ]
Bryce, A. H. [8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Dept, Houston, TX 77030 USA
[2] Mayo Clin, Ctr Canc, Dept Internal Med, Div Hematol Oncol, Jacksonville, FL 32224 USA
[3] Univ Colorado, Canc Ctr Anschutz Canc Pavil, Med Oncol, Aurora, CO USA
[4] Mayo Clin, Ctr Canc, Dept Oncol, Div Med Oncol, Rochester, MN USA
[5] Mayo Clin, Div Med Oncol, Dept Oncol, Rochester, MN USA
[6] Phosplatin Therapeut LLC, R&D, New York, NY USA
[7] Phosplatin Therapeut LLC, Clin Dev, New York, NY USA
[8] Mayo Clin, Ctr Canc, Dept Internal Med, Div Hematol Oncol, Phoenix, AZ USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1026MO
引用
收藏
页码：S708 / S708
页数：1
相关论文
共 50 条
  • [1] A phase 1b study of novel immunogenic cell death inducer PT-112 plus PD-L1 inhibitor avelumab in metastatic castrate-resistant prostate cancer (mCRPC) patients.
    Bryce, Alan Haruo
    Dronca, Roxana Stefania
    Costello, Brian Addis
    Aparicio, Ana
    Subudhi, Sumit Kumar
    O'Donnell, Joseph F.
    Jimeno, Jose
    Yim, Christina Yeaeun
    Ames, Tyler David
    Price, Matthew
    Karp, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours
    Karp, Daniel D.
    Camidge, D. Ross
    Infante, Jeffery R.
    Ames, Tyler D.
    Price, Matthew R.
    Jimeno, Jose
    Bryce, Alan H.
    ECLINICALMEDICINE, 2022, 49
  • [3] PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors
    Karp, D. D.
    Camidge, D. R.
    Infante, J. R.
    Ames, T. D.
    Jimeno, J. M.
    Bryce, A. H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
    Bryce, Alan Haruo
    Karp, Daniel D.
    Tagawa, Scott T.
    Nordquist, Luke T.
    Rathkopf, Dana E.
    Adra, Nabil
    Dorff, Tanya B.
    Baeck, Johan
    O'Donnell, Joseph Francis
    Ames, Tyler David
    Yim, Christina Y.
    Price, Matthew
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] PT-112 in advanced metastatic castrate-resistant prostate cancer (mCRPC), as monotherapy or in combination with PD-L1 inhibitor avelumab: Findings from two phase I studies
    Bryce, Alan Haruo
    Dronca, Roxana Stefania
    Costello, Brian Addis
    Infante, Jeffrey R.
    Ames, Tyler David
    Jimeno, Jose
    Karp, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
    Infante, Jeffrey R.
    Hansen, Aaron Richard
    Pishvaian, Michael J.
    Chow, Laura Quan Man
    McArthur, Grant A.
    Bauer, Todd Michael
    Liu, Stephen V.
    Sandhu, Shahneen Kaur
    Tsai, Frank Yung -Chin
    Kim, Jeong
    Stefanich, Eric
    Li, Chi -Chung
    Gilber, Houston
    Mccall, Bruce
    Anderson, Maria S.
    Huseni, Mahrukh
    Rhee, Ina Park
    Siu, Lillian L.
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients
    Lakhani, Nehal J.
    Patnaik, Amita
    Liao, John B.
    Moroney, John William
    Miller, David S.
    Fleming, Gini F.
    Axt, Matt
    Wang, Yan V.
    Agoram, Balaji
    Volkmer, Jens-Peter
    Maute, Roy
    Schroeder, Andreas
    Chico, Isagani
    Chao, Mark
    Takimoto, Chris H. M.
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [8] Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours
    Strauss, J.
    Vugmeyster, Y.
    Sznol, M.
    Pachynski, R. K.
    Trang, K.
    Chennoufi, S.
    Gulley, J. L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
    Jayesh Desai
    Peter Fong
    Victor Moreno
    Sophia Frentzas
    Tarek Meniawy
    Ben Markman
    Mark Voskoboynik
    Tahmina Rahman
    Nageshwar Budha
    John Wu
    Jin Marlow
    Silu Yang
    Emiliano Calvo
    Juan Martin-Liberal
    British Journal of Cancer, 2023, 128 : 1418 - 1428
  • [10] A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
    Desai, Jayesh
    Fong, Peter
    Moreno, Victor
    Frentzas, Sophia
    Meniawy, Tarek
    Markman, Ben
    Voskoboynik, Mark
    Rahman, Tahmina
    Budha, Nageshwar
    Wu, John
    Marlow, Jin
    Yang, Silu
    Calvo, Emiliano
    Martin-Liberal, Juan
    BRITISH JOURNAL OF CANCER, 2023, 128 (08) : 1418 - 1428
12345